Abstract Alzheimer's disease (AD) is characterized by the presence of neuropathological lesions containing amyloid plaques (APs) and neurofibrillary tangles (NFTs) associated with neuroinflammation and neuronal degeneration. Hippocampus is one of the earliest and severely damaged areas in AD brain. Glia maturation factor (GMF), a known proinflammatory molecule is up-regulated in AD. Here, we have investigated the expression and distribution of GMF in relation to the distribution of APs and NFTs in the hippocampus of AD brains. Our immunohistochemical results showed GMF is expressed specifically in the vicinity of high density of APs and NFTs in the hippocampus of AD patients. Moreover, reactive astrocytes and activated microglia surrounds the APs and NFTs. We further demonstrate that GMF immunoreactive glial cells were increased at the sites of Tau containing NFTs and APs of hippocampus in AD brains. In conclusion, up-regulated expression of GMF in the hippocampus, and the co-localization of GMF and thioflavin-S stained NFTs and APs suggest that GMF may play important role in the pathogenesis of AD.
Introduction
Alzheimer's disease (AD) is the most common progressive neurodegenerative disease characterized by the presence of neuropathological lesions with amyloid plaques (APs) and hyperphosphorylated Tau containing neurofibrillary tangles (NFTs) associated with neuroinflammation and neuronal degeneration [1] [2] [3] . Among the affected regions, hippocampus and entorhinal cortex are major brain areas that show neuropathological lesions of AD. The hippocampus, a brain area critical for learning and memory, is especially vulnerable to damage at early stages AD [4, 5] . Both hippocampus and entorhinal cortex has direct connectivity and are crucial area for memory associated functions. Further, these regions are most vulnerable brain sites during the early progression of AD. During the normal aging processes and AD, hippocampus and entorhinal cortex are independently and heavily affected. A specific sub region of hippocampus is affected in different neurodegenerative diseases [6] . Previous studies have shown a loss of 25-70 % of the neurons in different regions of hippocampus in AD patients [7] . Most of the AD cases had NFTs and APs in the hippocampal areas as well as in entorhinal cortex [8] . Atrophy of hippocampus and entorhinal cortex was seen in very early AD [9] [10] [11] . Previous studies showed loss of neurons in the hippocampal formation in AD brains [12, 13] . The number of NFTs in the medial temporal lobe structures, including hippocampal formation and entorhinal cortex, is well correlated with the cognitive memory impairment in AD patients [14, 15] . The memory loss is one of the earliest symptoms in AD patients due to the destruction of entorhinal cortex projections, the perforant pathways to the hippocampal formation [16, 17] . Recent studies suggest that inflammatory reactions play critical role in the progression of the pathogenesis of AD [18] [19] [20] .
It is known that the severity of AD pathology clearly associates with number of reactive astrocytes and activated microglia in the brain. These glial cells contribute to the progression of neuroinflammation in AD through releasing several proinflammatory molecules [21] .
Glia maturation factor (GMF) is one of the proinflammatory molecules that mediate inflammation in the neurodegenerative and demyelinating diseases in the central nervous system (CNS) [3, 21, 22] . GMF was first discovered, purified, sequenced, and sub-cloned from bovine brain in our laboratory [23] [24] [25] . GMF is mainly localized in the glia and in some neurons of the CNS. GMF in excess induces proinflammatory reactions and acts as a prominent mediator of inflammation in the CNS leading to the death of neurons in neurodegenerative diseases such as in AD [21, 26] . Our previous studies have shown that GMF is expressed in the vicinity of APs and NFTs in the temporal cortex of human AD brains [3, 27] . Though GMF's involvement in neuroinflammation is clearly known, the distribution of GMF in the hippocampus is not yet thoroughly investigated in AD brains. Therefore, the present study was carried out to evaluate the expression and the association between GMF expressing glial cells and neuropathological hallmarks such as NFTs and APs distribution in the hippocampal regions in the AD patients. We showed specific up-regulation of GMF expression in the glial cells is associated with increased number of NFTs and APs in the hippocampus of AD brain.
Materials and Methods

Human AD Brain Hippocampus
Human temporal lobes containing hippocampal region from human post mortem rapid brains of AD patients and control non AD subjects were obtained from the University of Iowa Deeded body program. We have used six AD cases which include brains from three male and three female and age ranging between 68 and 88 years as well as three control non AD brains with age ranging between 76 and 84. Temporal lobes were then fixed with 4 % paraformaldehyde solution [in 0.1 M phosphate buffered saline pH 7.4 (PBS); GIBCO, Life Technologies, Grand Island, NY, USA] for 24-48 h. Then the fixed temporal lobe blocks were cut into 50 lm thick sections using a sledge freezing microtome. These sections were collected in PBS and stored in cryostorage solution (glycerol 30 ml, ethylene glycol 30, 40 ml 0.1 M PBS) at 80°C until used for immunohistochemical staining (IHC). The neuropathological evaluation of tissue was performed by using thioflavin-S (Sigma, St. Louis, MO, USA) histochemical staining to detect the presence of AD specific histopathological hallmarks NFTs and APs as we have reported previously [28, 29] . Brains which showed the presence of laminar localization pattern, increased density of Tau containing NFTs and APs in the hippocampal and temporal cortical regions were confirmed as AD brains [28] [29] [30] [31] . All the experimental procedures were carried out according to the Institution approved guidelines.
Immunohistochemistry
Sections containing hippocampus were removed from cryostorage solution and washed in PBS for 10 min and IHC was performed as we have reported previously [28, 29] . Briefly, free floating sections were incubated with 0.3 % hydrogen peroxide for 20 min at room temperature (RT) to quench the endogenous peroxidase activity. Sections were then washed in PBS and then incubated with 5 % normal goat serum for 1 h at RT to block nonspecific staining. Then the sections were incubated with primary antibodies to GMF (G2-O9-monoclonal antibody, custom made antibody, 1:500 dilutions), glial fibrillary acidic protein (GFAP; anti-GFAP, clone GA5 monoclonal antibody, Millipore, Temecula, CA, USA; 1:500 dilutions) and ionized calcium binding adaptor molecule 1 (IBA-1, Wako Chemicals, Richmond, VA, USA; 1:500 dilutions), neuronal nuclei (NeuN; 1:1,000, Chemicon, Temecula, CA, USA); calbindin (1:10,000, Swant, Bellinzona, Switzerland); AT8 (Innogenetics, Ghent, Belgium; 1:1,000 dilutions), diluted in blocking buffer for overnight at 4°C. Sections were then washed in PBS and incubated for 1 h at RT with corresponding biotinylated secondary anti-mouse IgG or anti-rabbit IgG antibodies raised in goat (Vector Laboratories, Burlingame, CA, USA). Then the sections were rinsed again in PBS and developed with an avidinbiotin peroxidase complex (ABC) standard staining kit (Vector Laboratories) solution diluted in PBS for 1 h at RT. After washing in PBS, the sections were developed with diaminobenzidine (DAB substrate kit, Vector Laboratories) substrate solution. Negative staining controls were processed similarly, but without the primary antibody. The sections were rinsed with distilled water and mounted on the glass slides and dried. Slides were then dehydrated and cover slipped with Permount (Fisher Scientific, Pittsburgh, PA, USA). All the washings were carried out in PBS for three times and 10 min/wash. Double Staining with GMF, GFAP, Ionized Calcium Binding Adaptor Molecule 1 (IBA-1) and Thioflavin-S Sections of hippocampus were incubated with antibodies to GMF (G2-O9-monoclonal antibody), GFAP; anti-glial fibrillary acidic protein, clone GA5 monoclonal antibody, Millipore, MA, USA, for immunoreactive astrocytes) and IBA-1 (Anti-IBA-1, polyclonal antibody, Wako Chemicals for activated microglia) individually by the IHC procedure as we described above. GMF, GFAP or IBA-1 immunolabelled sections from the hippocampus were then counterstained with thioflavin-S to show the association between GMF, GFAP or IBA-1 with NFTs or APs in AD. Further, we also counted the number of APs, the number of GMF, GFAP (reactive astrocytes) and IBA-1 (activated microglia)-positive cells in the dense APs regions and sparse APs regions of hippocampus of AD brains. The results were analyzed by unpaired 'T' test and the p value of \005 were considered significant. The data were expressed as mean ± SEM. Double IHC Staining of GMF with 6E10, and GMF with Tau IHC of GMF was first performed as we have described previously [3, 27] except that SG peroxidase substrate (Vector Laboratories) was used instead of DAB substrate. After visualization of immunoreactivity with DAB for 5 min, sections were rinsed in PBS, blocked with 5 % normal goat serum for 1 h at RT and then incubated with primary antibodies for 6E10 (Beta Amyloid, 1-16 (6E10) monoclonal antibody; Covance, MA, USA) for APs or Tau mainly for NFTs for overnight at 4°C, followed by secondary antibody for 1 h at RT. After washing with PBS, the slides were then incubated with ABC solution for 1 h at RT. SG peroxidase substrate (Vector Laboratories) was used as a second substrate. Sections were then dehydrated and mounted using Permount. Double IHC for Calbindin and Thioflavin-S Double IHC was carried out as mentioned above with Calbindin (Swant), thioflavin-S (Sigma) to localize calbindin distribution with NFTs and APs.
NeuN and Nissl Staining
NeuN IHC was carried out to study the neuronal distribution in the hippocampus. Nissl staining was done for the study of neuronal architecture of hippocampus as reported previously [28, 29] .
Results
Expression of GMF in the Hippocampus of AD Brain
Neuronal loss is also major pathological changes in AD brain. We observed neuronal loss in CA1 region in hippocampus of AD brain by using Nissl (Fig. 1a) staining and NeuN IHC (Fig. 1a) . We then performed doubleimmunolabeling of calbindin (for interneurons) and thioflavin-S histochemistry in the cornu ammonis (CA1) field of the hippocampus of AD. Bright field images of calbindin immunostained (Fig. 1b) combined with thioflavin-S fluorescence images (Fig. 1b) We have examined the expression of GMF-containing cells and its morphological relationships with the neuropathology in the CA1 region of hippocampus in AD (Fig. 1c) and non AD (Fig. 1d) brains using single and double immuno-labeling methods. GMF immunoreactivity was higher in glial cells and neurons in hippocampus of AD brain when compared to non AD brain. Hippocampal regions showed strong GMF immunoreactive glial cells (Fig. 2a, b ) and these cells were associated with APs and NFTs (Fig. 2c, d, arrows) . Accumulation of GMF immunoreactive cells were observed throughout the hippocampus in AD. Thioflavin-S stained NFTs and APs were found in a large numbers in the CA2, subfield of hippocampus. GMF immunoreactivity was observed strongly in the glial cells in the vicinity of APs (Fig. 3a-d) . GMF immunoreactive glial cells were clustered within thioflavin-S stained APs and their vicinity as shown in CA4 region (Fig. 3c, d ).
GMF, GFAP and IBA-1 Co-localization with APs and NFTs in the Hippocampus of AD Brain
We next performed double labeling of GMF immunoreactivity, GFAP-immunoreactive astrocytes and IBA-1 labeled activated microglia with APs (arrows) and NFTs by thioflavin-S staining in the hippocampus containing (Fig. 4a ) dense plaque region, (Fig. 4b) sparse APs region, and (Fig. 4c ) no plaque region (only GMF staining) of AD brain. Note the presence of GMF immunoreactive glial cells, reactive astrocytes and activated microglia within the APs and also located inside the APs in the merged figures (arrows). The number of APs and the number of positive cells for GMF (Fig. 4d 1,1 0 ), GFAP (Fig. 4d 2,2 0 ) and IBA-1 (Fig. 4d 3,3 0 ) were counted in the dense APs regions and sparse APs regions. We observed that the expression of GMF, GFAP and IBA-1 were increased in dense plaque regions. We considered dense region if the number of APs above [2/95 mm 2 .
Double Immunostaining of 6E10 and GMF, Tau and GMF in the Hippocampus in AD Brain
Next, we also confirm the association of GMF with APs and NFTs using other antibodies. In hippocampal sections double-immunostaining for GMF and APs (6E10 antibody; Fig. 5b ), NFTs (Tau antibody), the close association between GMF immunoreactive glial cells (Fig. 5b) seen in the hippocampus of AD brain. Vast majority of the GMF positive cells showed similar morphological features of reactive astrocytes and these cells were frequently appeared ramified morphology. GMF immunoreactivity was clustered within and around 6E10-positive APs (Fig. 5b) and AT8 stained APs and NFTs.
Discussion
In the present study we report that hippocampal cells express high levels of GMF and that GFAP immunoreactive astrocytes were increased in the hippocampus of AD brain. In the hippocampus, GMF concentration is higher specifically at the sites of APs and hyperphosphorylated Tau containing NFTs, the pathological hallmarks of AD. We found that high density of GMF immunoreactive glial cells are present in all areas of the hippocampus.
AD is due to the loss of selective neurons in the entorhinal cortex, basal forebrain, amygdala, hippocampus, and cortical areas, as well as progressive deficits of cognition and memory functions. Hippocampus is important for learning and memory and is especially vulnerable to damage at the early stages of AD [5] . Deterioration of hippocampal function induced by Ab oligomers contributes to the memory deficits associated with AD. Hippocampus neuronal metabolic gene expression outperforms whole tissue data in predicting AD progression [32] indicating crucial role of hippocampus in the AD pathogenesis. Increased GFAP expression in the CNS is due to stress, infection and normal aging process as a compensatory response with reactive astrocytosis and gliosis. Age of the astrocyte and the expression levels of GFAP have negative impact on the viability and neurite outgrowth of the neurons in the vicinity. It is therefore possible that increased GFAP and Iba-1 in the reactive astrocytes and activated microglia, respectively in the hippocampus along with increased level of GMF expression co-localization as observed in our present study might influence the neuronal activity making it more susceptible to age-associated neurodegeneration and cognitive impairment as previously reported [33] . It is known that during normal aging process, hippocampus is subjected to widespread oxidative stress, loss of antioxidant function [34] and enhanced GFAP expression along with increased level GMF might make them particularly more susceptible to neuronal degeneration. Ab accumulation is associated with hippocampal network dysfunction and the hippocamposeptal neuron populations are specific targets for Ab deposits in AD. Our present study showed high levels of Ab as observed by increased plaques in the AD affected hippocampal regions. Hippocampal pathology is central to AD and other forms of dementia. Autopsy studies have shown that certain hippocampal subfields are more vulnerable than others to AD, in particular the subiculum and cornu ammonis 1 (CA1) and CA3 [6, 35] . Our present study also revealed that hippocampal regions showed more GMF immunoreactivity which is associated with high density of NFTs and APs and specifically showed more number of large plaques. This colocalization indicates that GMF expression is strongly associated with the pathogenesis of AD. Hippocampal neuron loss has been well-documented in AD brains [13] . Moreover, it seems this decrease of hippocampal neuronal density is more prominent especially at the CA1 and also in the CA3 hippocampal areas in human AD brain [36] .
Neuronal death in AD is known to be mediated by APs and the NFTs. However, several recent reports support that other factors such as the local inflammatory reactions accompanied by inflammatory cell infiltrations and activation, inflammatory molecule release by microglia and astrocytes also significantly contribute to the severity of the pathogenesis of AD [35, [37] [38] [39] . For example, gliosis and microglial activation in relation to APs is a common feature in AD. Glial cells are not only known to secrete proinflammatory and vasoactive molecules, but also known to release toxic substances capable of causing neuronal degeneration and neuronal death [38] . We have previously reported that glial cells express GMF in the temporal cortex of AD brain [3] . High GMF expression by the glial cells may augment or synergize with other inflammatory molecules of the CNS in chemoattraction, proliferation, activation and release of inflammatory mediators from glial cells and inflammatory cells and therefore may exacerbate the pathogenesis in AD. Factors triggering excessive synthesis and secretion of GMF in the CNS are not yet clearly understood. However, increased number of APs, NFTs, inflammatory cells and inflammatory molecules may induce the up-regulation of GMF expression and GMF may acts as an autocrine and/or paracrine signaling manner in the CNS of AD patients. Since GMF is known to be localized on the glial cell surface [40] , it appears that cell-surface GMF could act on the target cells such as astrocytes, microglia, neurons and other inflammatory cells at close range when those cells are in direct cell-to-cell contact.
In accord with our previous results that strong association exists between GMF expression and APs in the temporal cortical region [3] . In AD, both hippocampus and entorhinal cortex are first affected regions and then the pathogenesis extends to inferior temporal cortical regions.
Previous studies by others have shown that some APs were associated with inflammation by the presence of reactive astrocytes in the vicinity of APs and activated microglia within the APs [41] [42] [43] [44] . Our previous study has shown the colocalization of GMF and reactive astrocytes in the vicinity of APs and NFTs in the temporal cortex of AD brains [3] . Our present study has shown strong correlation between GMF with NFTs and APs in the hippocampus of AD patients. Inhibition of microglial activation has been reported to protect hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for AD [5] .
GMF is one of the proinflammatory molecules known to mediate inflammation in the neurodegenerative and demyelinating diseases in the CNS [3, 21, 22, 26, 27, 45] . The expression and distribution of GMF within the CNS has been investigated previously using IHC staining procedures [40, 46] . We have previously shown that, GMF protein and mRNA are widely expressed in the spinal cord, cerebellum, midbrain, basal ganglia, sensory and motor cortex and entorhinal cortex [47] . Our present results are in agreement with the previous results. Moreover, we have recently shown that GMF induces IL-33 and TNF-a release from mouse astrocytes and that IL-33 in turn mediates neurodegeneration and neuronal death [48] . TNF-a is already known to induce neuronal death in neuroinflammatory conditions [49] .
In conclusion, the increased expression of GMF in the hippocampus of AD brain, and the co-localization of GMF and thioflavin-S stained NFT and APs suggest that the GMF may play important roles in the pathogenesis of AD.
